Cyteir Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 12.49 million compared to USD 14.1 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.4 a year ago.
Cyteir Therapeutics, Inc.
Equities
CYTT
US23284P1030
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |